Year-end Sale % OFF 
Abstract
HighlightsA novel all-in-one fluorescent nanomedicine platform based on silicon nanoparticles (SiNPs) was developed for imaging-guided co-delivery of short interfering RNA (siRNA) and doxorubicin (DOX).The intracellular time-dependent release behaviors of siRNA and DOX were visually monitored by tracking the strong and stable fluorescence of SiNPs.The SiNPs-based nanocarriers displayed pronounced therapeutic efficiency on drug-resistant breast cancer cells.
Highlights
Despite great progress in cancer treatment, multidrug resist‐ ance (MDR), which can lead to high recurrence rates and treatment failures, remains a tremendous challenge in cancer chemotherapy [1]
Transmission electronic microscopy (TEM) images revealed the spherical shape of the silicon nanoparti‐ cles (SiNPs)-DOX/small interfering RNA (siRNA) nanocomposites, with a diameter of ~ 6.3 nm (Fig. 1b, c)
We developed a novel fluorescent SiNPs-based nanomedi‐ cine platform, which is useful for imaging-guided co-deliv‐ ery of siRNA and doxorubicin, enabling the enhancement of therapeutic efficacy in drug-resistant cancer cells
Summary
Despite great progress in cancer treatment, multidrug resist‐ ance (MDR), which can lead to high recurrence rates and treatment failures, remains a tremendous challenge in cancer chemotherapy [1]. Novel, fluorescent, all-in-one nanocarriers with superior optical properties (e.g., high and stable fluorescence) and excellent biocompatibility are needed to facilitate the development of imaging-guided RNAi-based combination therapy in drug-resistant cancer cells. The prepared SiNPs-based nanocarri‐ ers with adjustable drug-loading capacity were very suit‐ able for optical imaging-guided cancer therapy because of their high fluorescence and robust photostability. It remains unknown whether these nanocarriers are available for imaging-guided co-delivery of siRNA and chemothera‐ peutic agents, facilitating the enhancement of the therapeutic efficacy in MDR cancer cells. Our results suggest that SiNPs-based fluorescent nanocomposites can be used as imaging-guided RNAi-based co-delivery nanoagents for the treatment of MDR cancer cells
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
